Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Humacyte, Inc. (HUMA) stock declined 2.86% to $0.50, underperforming broader market gains. The stock has lost 13.23% over the past month. While the company expects EPS to improve 35.71% next quarter with revenue up 14.67%, full-year projections show earnings declining 53.85% despite revenue doubling. The stock holds a Zacks Rank #4 (Sell) rating, and its industry ranks in the bottom 27% of all sectors.